Intravenous administration of synthetic TRF in doses of 250-750 µg stimulates a rise in plasma HTSH levels in normal individuals. No rise in plasma HTSH occurs following 500-750 µg of TRF in subjects on 0.3 mg of Lthyroxine or in patients with panhypopituitarism. One of two euthyroid patients with a sella tumor appeared to respond suboptimally to TRF. It is condluded that synthetic TRF is a convenient means for testing the integrity of the human pituitary for TSH secretion.
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Clinical Biochemistry
- Biochemistry, medical